Question 1

What makes ipamorelin different from other GH peptides?

Accepted Answer

Ipamorelin's defining feature is its selectivity — it stimulates GH release with minimal effects on cortisol, prolactin, and appetite. Older GHRPs like GHRP-6 and GHRP-2 raise GH effectively but also significantly elevate cortisol and (in GHRP-6's case) dramatically increase appetite. Ipamorelin achieves comparable GH release without these off-target effects, making it better tolerated for most patients.

Question 2

How much GH does ipamorelin release?

Accepted Answer

At standard doses (1-3 mcg/kg or approximately 100-300 mcg), ipamorelin produces peak GH levels of approximately 10-30 ng/mL, occurring about 30-45 minutes after subcutaneous injection. The exact response varies by individual based on age, pituitary reserve, body composition, and fasting state. Combining with CJC-1295 can increase the GH response by 2-3x.

Question 3

Does ipamorelin increase appetite?

Accepted Answer

Ipamorelin produces minimal appetite stimulation compared to other GHRPs. While it does activate the ghrelin receptor (which plays a role in hunger signaling), its appetite effects are generally mild or absent at standard doses. This is a major advantage over GHRP-6, which causes intense hunger in most users within 15-30 minutes of injection.

Question 4

Why is ipamorelin combined with CJC-1295?

Accepted Answer

They work through different receptor pathways — ipamorelin through the ghrelin receptor (GHS-R1a) and CJC-1295 through the GHRH receptor. Stimulating both pathways simultaneously produces synergistic GH release approximately 2-3x greater than either peptide alone. The combination preserves pulsatile GH release patterns when using the no-DAC version of CJC-1295.

Question 5

Is ipamorelin safe long-term?

Accepted Answer

Ipamorelin has not been studied in multi-year human trials, so long-term safety data is limited. Short-term human data shows a favorable side effect profile. Theoretical long-term concerns include IGF-1 elevation (cancer risk), glucose metabolism effects, and potential pituitary desensitization with continuous use. Regular monitoring of IGF-1, fasting glucose, and HbA1c is recommended during ongoing treatment.

Question 6

When should I take ipamorelin?

Accepted Answer

Ipamorelin should be injected subcutaneously on an empty stomach — at least 90 minutes after your last meal. Most protocols recommend bedtime injection to augment the natural nocturnal GH surge during deep sleep. Some protocols include a second dose upon waking (still fasted) or 30 minutes before exercise. Avoid eating for at least 30 minutes after injection.

Question 7

Why is ipamorelin vendor quality a concern?

Accepted Answer

Our testing of 261 samples from 41 vendors found that 69% of ipamorelin samples showed greater than 10% deviation between labeled and actual peptide quantity. This means most ipamorelin products deliver a meaningfully different dose than intended. Since ipamorelin's selectivity advantage is dose-dependent, receiving the wrong dose can either reduce effectiveness (underdosed) or eliminate the selectivity benefit (overdosed).

Question 8

GHS-R1a Receptor Activation The ghrelin receptor (GHS-R1a) is expressed primarily in the anterior pituitary gland and the hypothalamus. When ipamorelin binds to GHS-R1a on pituitary somatotroph cells, it triggers intracellular calcium influx and GH release from secretory granules. This mechanism is complementary to — not competitive with — the GHRH receptor pathway used by sermorelin, tesamorelin, and CJC-1295. This complementary mechanism is why combining ipamorelin with a GHRH analog (most commonly CJC-1295 no-DAC) produces synergistic GH release — two different receptor pathways converging on the same somatotroph cells to maximize GH pulse amplitude. Why "Selective"?

Accepted Answer

The term "selective" specifically refers to ipamorelin's limited off-target effects compared to other GHS-R1a agonists. The selectivity appears to be a function of ipamorelin's specific binding characteristics: Cortisol: GHRP-6 at GH-releasing doses produces significant cortisol elevation (20-40% increase). GHRP-2 produces moderate cortisol elevation (10-20% increase). Ipamorelin produces negligible cortisol changes — typically fewer than 5% from baseline at standard doses. Prolactin: Similar pattern — older GHRPs cause meaningful prolactin elevation while ipamorelin does not. This is clinically relevant because chronic prolactin elevation can cause gynecomastia, sexual dysfunction, and menstrual irregularities. Appetite: While ipamorelin does activate the ghrelin receptor (which plays a r

#	Vendor	Avg score	Purity range	Tests	Verified $/mg	Grade	Profile
Grade A — Great
1	Peptide Partners	9.9	99.1 – 100.0%	7	$1.40	A	review →
2	Paradigm Peptide	9.0	98.8 – 100.0%	6	—	A	review →
Grade B+ — Very Good
3	Astro Peptides	8.6	98.4 – 99.6%	7	—	B+	review →
4	Aavant Research	8.2	98.2 – 99.4%	5	—	B+	review →
5	Polaris Peptides	8.0	98.3 – 99.5%	5	—	B+	review →
Grade B — Good
6	Limitless Life Nootropics	7.2	97.9 – 99.1%	4	—	B	review →

Vendor Rankings

Ipamorelin Rankings